Zeria Pharmaceutical Co., Ltd. announced consolidated and non-consolidated earnings results for the full year ended March 31, 2016. For the period, the company reported net sales of JPY 62,475 million, operating income of JPY 4,565 million, ordinary income of JPY 4,450 million, profit attributable to owners of parent of JPY 3,513 million or JPY 66.15 per share compared to net sales of JPY 61,012 million, operating income was JPY 2,678 million, ordinary income of JPY 2,770 million, profit attributable to owners of parent was JPY 2,557 million or JPY 48.15 per share for the same period a year ago. Cash flows from operating activities were JPY 5,694 million against JPY 653 million for the same period a year ago. Net assets was JPY 1,199.94 compared with JPY 1,178.00 a year ago.

For the period, on non consolidated basis, the company reported net sales of JPY 48,269 million, operating income of JPY 1,388 million, ordinary income of JPY 2,589 million, profit of JPY 2,599 million or JPY 48.93 per share compared to net sales of JPY 48,872 million, operating income was JPY 587 million, ordinary income of JPY 1,733 million, profit was JPY 2,292 million or JPY 43.16 per share for the same period a year ago. Net assets was JPY 1,007.44 compared with JPY 999.71 a year ago.

The company provided consolidated earnings guidance for the first six months and full year ending March 31, 2017. For the six months, the company expects net sales of JPY 32,000 million, operating income of JPY 2,200 million, ordinary income of JPY 2,000 million, profit attributable to owners of parent of JPY 1,800 million or JPY 33.89 per share.

For the full year of 2017, the company expects net sales of JPY 66,000 million, operating income of JPY 4,800 million, ordinary income of JPY 4,600 million, profit attributable to owners of parent of JPY 3,600 million or JPY 67.78 per share.